Zykadia for ALK Positive Lung Cancer: New Drug, New Hope

GRACEcast by Howard (Jack) West, MD

Jul 13, 201407:22Science & Medicine

The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.

Related Episodes

Continue listening to more episodes from GRACEcast.

Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?

Jul 31, 2014 - 04:36

Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung canc...

Management of Rare Kidney Tumors

Jul 29, 2014 - 01:55

What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for...

Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?

Jul 27, 2014 - 05:28

The doctors discuss the circumstances under which small cell lung cancer patients should receive prophyla...

NanoString Treatment for Kidney Cancer

Jul 24, 2014 - 02:03

NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and,...

Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?

Jul 22, 2014 - 02:27

Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lu...

How is the Heng Criteria Applied to Kidney Cancer Patients?

Jul 20, 2014 - 04:40

Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer pa...

Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

Jul 17, 2014 - 07:28

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab...

What is PD1 and PDL1 in Kidney Cancer?

Jul 15, 2014 - 03:15

Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and h...